Effects of cilostamide and forskolin on the meiotic resumption and embryonic development of immature human oocytes
BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. METHODS Cumulus–oocyte complexes retrieved from unstimulated ovari...
Saved in:
Published in | Human reproduction (Oxford) Vol. 23; no. 3; pp. 504 - 513 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Oxford University Press
01.03.2008
Oxford Publishing Limited (England) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. METHODS Cumulus–oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 µM cilostamide or 50 µM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days. RESULTS Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin. CONCLUSIONS Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis. |
---|---|
AbstractList | BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. METHODS Cumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 µM cilostamide or 50 µM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days. RESULTS Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin. CONCLUSIONS Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis. In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. Cumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 microM cilostamide or 50 microM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days. Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin. Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis. In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes.BACKGROUNDIn an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes.Cumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 microM cilostamide or 50 microM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days.METHODSCumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 microM cilostamide or 50 microM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days.Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin.RESULTSBoth cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin.Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis.CONCLUSIONSCombined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis. BACKGROUND: In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. METHODS: Cumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 mu M cilostamide or 50 mu M forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days. RESULTS: Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin. CONCLUSIONS: Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis. BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. METHODS Cumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 µM cilostamide or 50 µM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days. RESULTS Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin. CONCLUSIONS Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis. |
Author | Shu, Yi-min Ren, Zi Wang, Ning-ning Zeng, Hai-tao Zhuang, Guang-lun Shen, Hong-wei Yao, Shu-zhong Liang, Xiao-yan Ke, Pei-qi |
Author_xml | – sequence: 1 givenname: Yi-min surname: Shu fullname: Shu, Yi-min email: shuyimin@hotmail.com, 4Correspondence address. IVF Program, Department of Obstetric and Gynecology, Stanford University Medical Center, Palo Alto, CA 94304, USA. shuyimin@hotmail.com†These three authors contributed equally. organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China – sequence: 2 givenname: Hai-tao surname: Zeng fullname: Zeng, Hai-tao organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China – sequence: 3 givenname: Zi surname: Ren fullname: Ren, Zi organization: Department of Obstetrics and Gynecology, Guangdong Provincial People's Hospital, Guangzhou 510080, People's Republic of China – sequence: 4 givenname: Guang-lun surname: Zhuang fullname: Zhuang, Guang-lun organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China – sequence: 5 givenname: Xiao-yan surname: Liang fullname: Liang, Xiao-yan organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China – sequence: 6 givenname: Hong-wei surname: Shen fullname: Shen, Hong-wei organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China – sequence: 7 givenname: Shu-zhong surname: Yao fullname: Yao, Shu-zhong organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China – sequence: 8 givenname: Pei-qi surname: Ke fullname: Ke, Pei-qi organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China – sequence: 9 givenname: Ning-ning surname: Wang fullname: Wang, Ning-ning organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20200445$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18216034$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0s9rFDEUB_AgFbutHr3KIChexub3zBylVCsWPahQvIRM5g1NO0nGJCPuf2_WWfdQkJ4Skk8eL1_eCTrywQNCzwl-S3DHzm4WF2E-G8Axzh-hDeES15QJfIQ2mMq2JkSSY3SS0i3GZdvKJ-iYtJRIzPgGxYtxBJNTFcbK2CmkrJ0doNJ-qMYQ012YrK-Cr_INVA5syNZUEdLi5mzL8c6B6-M2-HIxwC-YwuzA511B65zOS4SqNKlLlWC2GdJT9HjUU4Jn-_UUfX9_8e38sr768uHj-bur2gghcm0aTCkfgI8CdxJrKaloaCNY34y47ZjWuO96CWA0k8Iw3uC-6RqujcBGc8FO0eu17hzDzwVSVs4mA9OkPYQlqaYEIFmJ4SFIcVuSFrzAl_fgbViiL59QlJCOEypoQS_2aOkdDGqO1um4Vf8yL-DVHuhk9DRG7Y1NB0cxxZj_7Z-tzsSQUoRRGZv1LvUctZ0UwWo3AWqdALVOQHlV33t1aOA__s3qwzI_SPelbcrw-4B1vFOyYY1Ql9c_1NdPXff5Wkgl2R82pNJn |
CODEN | HUREEE |
CitedBy_id | crossref_primary_10_1016_j_anireprosci_2014_06_026 crossref_primary_10_5653_cerm_2021_04413 crossref_primary_10_1007_s11626_015_9878_y crossref_primary_10_1016_j_theriogenology_2022_04_014 crossref_primary_10_1016_j_theriogenology_2016_02_029 crossref_primary_10_1093_humrep_det086 crossref_primary_10_33590_emj_10310074 crossref_primary_10_1093_biolre_ioz114 crossref_primary_10_1017_S096719941700017X crossref_primary_10_1186_s12958_022_00906_5 crossref_primary_10_1071_AN17895 crossref_primary_10_3390_ph14070684 crossref_primary_10_1016_j_repbio_2018_07_001 crossref_primary_10_1016_j_ejphar_2020_173293 crossref_primary_10_1016_j_theriogenology_2020_12_018 crossref_primary_10_1093_humupd_dmad023 crossref_primary_10_1186_s13048_023_01291_2 crossref_primary_10_1016_j_anireprosci_2016_09_003 crossref_primary_10_3389_fendo_2020_00548 crossref_primary_10_1016_j_livsci_2015_12_014 crossref_primary_10_1016_j_theriogenology_2014_07_042 crossref_primary_10_1093_humrep_den420 crossref_primary_10_1095_biolreprod_111_092858 crossref_primary_10_1186_s12958_018_0445_8 crossref_primary_10_1186_s13048_020_00704_w crossref_primary_10_1016_j_theriogenology_2012_09_020 crossref_primary_10_1038_s41598_023_32677_3 crossref_primary_10_1080_15384101_2018_1471316 crossref_primary_10_1095_biolreprod_108_074450 crossref_primary_10_1016_j_anireprosci_2015_05_012 crossref_primary_10_1038_cdd_2017_134 crossref_primary_10_25259_JRHM_5_2020 crossref_primary_10_1002_jcb_26171 crossref_primary_10_1095_biolreprod_113_114132 crossref_primary_10_3389_fendo_2019_00464 crossref_primary_10_1095_biolreprod_114_118471 crossref_primary_10_1095_biolreprod_113_110577 crossref_primary_10_1371_journal_pone_0126801 crossref_primary_10_1007_s10815_024_03272_w crossref_primary_10_1016_j_theriogenology_2020_12_009 crossref_primary_10_1093_humupd_dmx040 crossref_primary_10_1007_s12522_012_0134_9 crossref_primary_10_1111_rda_14021 crossref_primary_10_1016_j_theriogenology_2022_11_016 crossref_primary_10_1002_mrd_22307 crossref_primary_10_1016_j_theriogenology_2023_07_035 crossref_primary_10_1007_s43032_019_00137_x crossref_primary_10_1071_RD12341 crossref_primary_10_1016_j_fertnstert_2008_12_110 crossref_primary_10_1093_molehr_gat075 crossref_primary_10_1016_j_fertnstert_2008_12_111 crossref_primary_10_1016_j_livsci_2017_01_013 crossref_primary_10_1093_molehr_gax032 crossref_primary_10_1111_rda_12667 crossref_primary_10_1016_j_theriogenology_2016_04_013 crossref_primary_10_1016_j_mehy_2018_05_015 crossref_primary_10_1016_j_theriogenology_2016_12_015 crossref_primary_10_1017_S0967199415000064 crossref_primary_10_1007_s10815_013_0061_7 crossref_primary_10_1016_j_ejphar_2020_173115 crossref_primary_10_1530_REP_18_0173 crossref_primary_10_1186_s12958_020_0566_8 crossref_primary_10_1016_j_theriogenology_2016_01_008 crossref_primary_10_1016_j_theriogenology_2013_04_012 crossref_primary_10_1093_humrep_dex262 crossref_primary_10_1371_journal_pone_0030649 crossref_primary_10_1093_humrep_dev083 crossref_primary_10_1210_me_2008_0320 crossref_primary_10_1016_j_theriogenology_2021_06_003 crossref_primary_10_1016_j_theriogenology_2019_09_034 crossref_primary_10_1093_humrep_dep104 crossref_primary_10_1007_s10815_017_0958_7 crossref_primary_10_1016_j_anireprosci_2018_11_002 crossref_primary_10_1093_biolre_ioab176 crossref_primary_10_3390_jdb12020010 crossref_primary_10_1051_e3sconf_202128503013 crossref_primary_10_1016_j_fertnstert_2008_10_016 crossref_primary_10_1016_j_ijbiomac_2023_129149 crossref_primary_10_3390_genes14101885 crossref_primary_10_1016_j_fertnstert_2023_02_010 crossref_primary_10_1093_humrep_dew020 crossref_primary_10_1371_journal_pone_0068456 crossref_primary_10_1002_rmb2_12640 crossref_primary_10_1007_s10815_018_1365_4 crossref_primary_10_1016_j_jevs_2020_103112 crossref_primary_10_1093_humrep_deq246 crossref_primary_10_1186_1471_2350_13_121 crossref_primary_10_1071_RD17335 crossref_primary_10_1530_REP_15_0606 crossref_primary_10_3390_toxics10070355 crossref_primary_10_25259_JRHM_7_2020 crossref_primary_10_1371_journal_pone_0247518 crossref_primary_10_1093_humrep_deu329 crossref_primary_10_5005_jp_journals_10016_1251 |
ContentType | Journal Article |
Copyright | The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008 2008 INIST-CNRS The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org |
Copyright_xml | – notice: The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008 – notice: 2008 INIST-CNRS – notice: The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TM 8FD FR3 K9. P64 RC3 7ST 7U6 C1K 7X8 |
DOI | 10.1093/humrep/dem344 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nucleic Acids Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts Environment Abstracts Sustainability Science Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Genetics Abstracts Engineering Research Database Technology Research Database Nucleic Acids Abstracts Biotechnology and BioEngineering Abstracts Sustainability Science Abstracts Environment Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1460-2350 |
EndPage | 513 |
ExternalDocumentID | 1441409241 18216034 20200445 10_1093_humrep_dem344 10.1093/humrep/dem344 ark_67375_HXZ_SK99NX56_6 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -E4 .2P .55 .GJ .I3 .XZ .ZR 0R~ 1TH 29I 2WC 3O- 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAVLN AAWDT ABDFA ABEJV ABEUO ABGNP ABIME ABIXL ABJNI ABKDP ABMNT ABNHQ ABNKS ABPIB ABPQP ABPTD ABQLI ABQNK ABSMQ ABVGC ABWST ABXVV ABXZS ABZBJ ABZEO ACCCW ACFRR ACGFS ACPQN ACPRK ACUFI ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEHUL AEJOX AEKPW AEKSI AELWJ AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFQV AFFZL AFGWE AFIYH AFOFC AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGORE AGQPQ AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIJHB AJBYB AJDVS AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX ANFBD APIBT APJGH APWMN AQDSO AQKUS ARIXL ASAOO ASPBG ATDFG ATGXG ATTQO AVNTJ AVWKF AXUDD AYOIW AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BSCLL BSWAC BTRTY BVRKM BZKNY C1A C45 CAG CDBKE COF CS3 CXTWN CZ4 DAKXR DFGAJ DIK DILTD DU5 D~K E3Z EBS EE~ EIHJH EJD ELUNK EMOBN ENERS F5P F9B FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MBLQV MBTAY MHKGH ML0 N9A NGC NLBLG NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OBOKY OCZFY ODMLO OHT OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RIG RNI ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCN TCURE TEORI TJX TLC TMA TR2 W8F WH7 WOQ X7H X7M YAYTL YKOAZ YXANX ZGI ZKX ZXP ~91 6.Y AASNB AAYOK ABQTQ ABSAR ACMRT ADJQC ADRIX AFXEN KC5 M49 AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TM 8FD FR3 K9. P64 RC3 7ST 7U6 C1K 7X8 |
ID | FETCH-LOGICAL-c555t-c70224de4f50960a662572753b7f0893aa0b9b6eeca365c3470b7974ac50ca453 |
ISSN | 0268-1161 1460-2350 |
IngestDate | Fri Jul 11 00:29:52 EDT 2025 Mon Jul 21 11:27:23 EDT 2025 Fri Jul 25 04:09:52 EDT 2025 Mon Jul 21 06:00:00 EDT 2025 Mon Jul 21 09:16:20 EDT 2025 Thu Apr 24 22:50:28 EDT 2025 Tue Jul 01 00:38:55 EDT 2025 Wed Aug 28 03:24:43 EDT 2024 Tue Aug 05 16:49:42 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | meiotic resumption forskolin human oocyte cytoplasmic maturation cilostamide Human Embryonic development 3',5'-Cyclic-nucleotide phosphodiesterase Enzyme Enzyme inhibitor Esterases Phosphoric diester hydrolases Germinal cell Phosphodiesterase inhibitor Cilostamide Ripening Vertebrata Mammalia Hydrolases Oocyte |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c555t-c70224de4f50960a662572753b7f0893aa0b9b6eeca365c3470b7974ac50ca453 |
Notes | istex:D8807ACA3AEDA8C4971D11611D6FA01377207C87 ArticleID:dem344 ark:/67375/HXZ-SK99NX56-6 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://academic.oup.com/humrep/article-pdf/23/3/504/9543870/dem344.pdf |
PMID | 18216034 |
PQID | 211941252 |
PQPubID | 36115 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_70346360 proquest_miscellaneous_20809354 proquest_journals_211941252 pubmed_primary_18216034 pascalfrancis_primary_20200445 crossref_citationtrail_10_1093_humrep_dem344 crossref_primary_10_1093_humrep_dem344 oup_primary_10_1093_humrep_dem344 istex_primary_ark_67375_HXZ_SK99NX56_6 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2008-03-01 |
PublicationDateYYYYMMDD | 2008-03-01 |
PublicationDate_xml | – month: 03 year: 2008 text: 2008-03-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford – name: England |
PublicationTitle | Human reproduction (Oxford) |
PublicationTitleAlternate | Hum Reprod |
PublicationYear | 2008 |
Publisher | Oxford University Press Oxford Publishing Limited (England) |
Publisher_xml | – name: Oxford University Press – name: Oxford Publishing Limited (England) |
SSID | ssj0016186 |
Score | 2.2687037 |
Snippet | BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator,... BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator,... In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were... BACKGROUND: In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator,... |
SourceID | proquest pubmed pascalfrancis crossref oup istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 504 |
SubjectTerms | Adenylyl Cyclases - metabolism Adult Biological and medical sciences Cells, Cultured cilostamide Colforsin - pharmacology cytoplasmic maturation Drug Synergism Embryonic Development - drug effects Female forskolin Gap Junctions - drug effects Gap Junctions - physiology Gynecology. Andrology. Obstetrics human oocyte Humans Medical sciences Meiosis - drug effects meiotic resumption Oocytes - cytology Oocytes - drug effects Phosphodiesterase Inhibitors - pharmacology Quinolones - pharmacology |
Title | Effects of cilostamide and forskolin on the meiotic resumption and embryonic development of immature human oocytes |
URI | https://api.istex.fr/ark:/67375/HXZ-SK99NX56-6/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/18216034 https://www.proquest.com/docview/211941252 https://www.proquest.com/docview/20809354 https://www.proquest.com/docview/70346360 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwELfKJiEkhKDjEQbDSKhfWLYstpP24wSDwrQJaZ1U9UvkOI6ItiRVmwrKX8_5UacVVDy-RFFyeel-vtzZd79D6I3iMBchyfw-IdynIc983lezTaEIBQ8oobpc7OIyGl7Tz2M27nS-rVeXNOmR-PHbupL_0SocA72qKtl_0Ky7KRyAfdAvbEHDsP0rHZ-1yRhCdSRoeFlkZj0AfNH5jWrIY1cD3payqA1fM7yhsRNKTpbpbKm74GRt-pDmkShLzflpu_jVtVg2Nt_Q-rJm_l-xYmrSWIOjvqlAXJtguPq60Ha-8MvCIXEijY0Z8sJveO2WfYwRnBTtfPbCTmh_VDv-7aLamKfot4laR9LYVhoFfkgMz-zK-JpiYwsysmZJmelK_IuFN-xX8OnwebCTyZLQDUlQ0bTUCofQSTXRpu2vziUgrk7dQbshxBeq9cX7T-du-Uk1EbCErPC8Y_O0Y_MsRTNrr97wZXbVsPy-qpO8P-VzGGS56Y6yPXzRbszoIXpg4w98asD0CHVk1UV7pxVv6nKJe1hnBOulli66e2ETL7qo98VQnC8P8ait2Jsf6isc-flyD80sJnGd4zVMYsAadpjEdYUBk9hiEreY1HIOk3gNk-qGK0xijUlsMfkYXX84G70b-ravhy8YY40vYuU4ZpLminso4BHE4OBGM5LGeQD-M-dBOkgjKQUnEROExkEaQ9zLBQsEp4w8QTtVXclnCIs45lEs4yiLc0rCuH-Sqx4BhHIQTeWJhw5XGkqEJb1XvVduE5N8QRKj28To1kM9Jz41bC9bBbW6nRSf3agUyZglw_EkuTofDC7HLEoiD70GPPzpZgcbaHHSYaCsHWUe2l_BJ7HmZ54oakYK4UnooVfuLPwb1IIfr2S9ABEIBweE0e0S8L_XjIEeempQ2b6pxfjzrWf20b12nL9AO81sIV-Ch96kB3o0_QTGGevV |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+cilostamide+and+forskolin+on+the+meiotic+resumption+and+embryonic+development+of+immature+human+oocytes&rft.jtitle=Human+reproduction+%28Oxford%29&rft.au=Shu%2C+Yi-min&rft.au=Zeng%2C+Hai-tao&rft.au=Ren%2C+Zi&rft.au=Zhuang%2C+Guang-lun&rft.date=2008-03-01&rft.eissn=1460-2350&rft.volume=23&rft.issue=3&rft.spage=504&rft_id=info:doi/10.1093%2Fhumrep%2Fdem344&rft_id=info%3Apmid%2F18216034&rft.externalDocID=18216034 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0268-1161&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0268-1161&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0268-1161&client=summon |